Fulgent Genetics, Inc. FLGT
19.63 USD +0.26 (+1.33%)
Nov 4, 2026, 11:20 AM EST
19.57 Day range 19.99
13.79 52-week range 30.85
- YTD
- -25.29%
- 1 year
- -14.22%
Analyst view
Price target (mean) 27.67 +41.0% upside
Now 19.63
- Target (low)
- 26.00
- Target (mean)
- 27.67
- Target (high)
- 30.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.369 | -0.61 – -0.12801 | 0.28 | -231.8% | 75.39M | +6.9% | 2 |
| Next quarter | -0.12758 | -0.21 – -0.05274 | -0.01 | -1175.8% | 73.89M | +14.6% | 3 |
| Current year | -0.16188 | -0.65 – 0.32624 | -0.41 | +60.5% | 282.23M | -2.4% | 2 |
| Next year | -0.46394 | -0.66 – -0.28183 | -0.16188 | -186.6% | 324.21M | +14.9% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Mar 6, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Dec 7, 2023 | UBS | Initiated | — | Neutral |
| Oct 16, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Mar 2, 2023 | Credit Suisse | Maintained | — | Outperform |
| Dec 8, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 18, 2022 | Raymond James | Initiated | — | Outperform |
| Nov 14, 2022 | Credit Suisse | Maintained | — | Outperform |
| Nov 14, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 25, 2022 | Credit Suisse | Initiated | — | Outperform |
| May 16, 2022 | Piper Sandler | Maintained | — | Overweight |
| Jan 25, 2022 | Oppenheimer | Maintained | — | Outperform |
| Aug 10, 2021 | Credit Suisse | Maintained | — | Underperform |
| Mar 5, 2021 | Piper Sandler | Maintained | — | Overweight |
| Feb 1, 2021 | Oppenheimer | Maintained | — | Outperform |
| Jan 8, 2021 | Credit Suisse | Downgrade | Neutral | Underperform |
| Nov 24, 2020 | BTIG | Downgrade | Buy | Neutral |
| Sep 25, 2020 | Credit Suisse | Maintained | — | Neutral |
| Aug 20, 2020 | Oppenheimer | Initiated | — | Outperform |
| Jul 27, 2020 | Piper Sandler | Maintained | — | Overweight |
| Jun 17, 2020 | Piper Sandler | Maintained | — | Overweight |
| May 29, 2020 | BTIG | Initiated | — | Buy |
| May 5, 2020 | Credit Suisse | Maintained | — | Neutral |
| Nov 5, 2019 | Piper Sandler | Upgrade | Neutral | Overweight |
| Apr 26, 2019 | Credit Suisse | Downgrade | Outperform | Neutral |
| May 9, 2018 | Credit Suisse | Maintained | Outperform | Outperform |
| Mar 1, 2018 | Piper Sandler | Downgrade | Overweight | Neutral |
| Mar 1, 2018 | Credit Suisse | Maintained | Outperform | Outperform |
| Nov 7, 2017 | Credit Suisse | Maintained | — | Outperform |
| Aug 8, 2017 | Credit Suisse | Maintained | — | Outperform |